Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation. We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor.This was a phase 1 trial that included the analysis of pharmacokinetic and...